Unicycive Therapeutics Inc (UNCY)

$UNCY Dr. Gupta remained very optimistic this morning during the live presentation. It sounds like he is expecting a class too resubmission outcome which leaves a PDUFA date roughly June 2026, but he hinted that the class two is at the discretion of FDA. My Takeaway is that there is still a slim chance of class one

$UNCY #CAPR MY DREAMS STOCKS

$UNCY Dang! Market doesn’t look promising today.

$UNCY [Again]

$UNCY It's going to happen

$UNCY niceeee ***FOLLOW ME for more winning calls!***

$UNCY The Company has communicated the situation following OLC CRL in press releases and shareholder meetings, along with a timeline (anticipated) to re-file for FDA review and PDUFA (hopefully). The CEO is now going on a tour to socialize that more broadly in December (see below) to institutional investors again for 1H-2026 target. Read the presentation material cited in my prior posts and on the Company website, review the efficacy and tolerability data, note that the CRL was due to a manufacturing sub-supplier that has since been resolved through two possible alternatives and a coarse timeline with the FDA estimated. Average PT here is $47, ranges from $21-90 while it still trades at $6.3. Multiplier upside on FDA re-file, PDUFA (1H-2026), IMO https://www.stocktitan.net/news/UNCY/unicycive-therapeutics-to-participate-in-upcoming-investor-events-in-25liodkllcda.html

$UNCY solid day people. Biotech as a whole had a great run today. It’s gonna be a sweet December. Happy Thanksgiving to all.

$UNCY it was a good day

$UNCY is

Unicycive Therapeutics (Nasdaq: $UNCY ) announced that CEO Dr. Shalabh Gupta will participate in two investor events in December: a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:00 a.m. ET, and a Noble Capital Markets Virtual Presentation on Wednesday, December 10, 2025, at 10:00 a.m. PT. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/unicycive. These presentations offer an opportunity for investors and healthcare industry professionals to hear about Unicycive’s clinical programs and corporate strategy directly from company leadership. A link to the live and archived Piper Sandler webcast, as well as an archived link of the Noble presentation, may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your Piper Sandler conference representative. See the press release at https://ir.unicycive.com/news/detail/115/unicycive-therapeutics-to-participate-in-upcoming-investor-events-in-december Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. The company’s lead investigational treatment, oxylanthanum carbonate, is a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Its second program, UNI-494, is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. Led by CEO Dr. Shalabh Gupta, MD and a seasoned executive team including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, and Dr. Guru Reddy, Unicycive is committed to addressing unmet needs in kidney disease treatment. Learn more at Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/). Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

$UNCY $5.52 ask DAC (dollar average cost adjusted for split) $3.85 Unicycive Therapeutics was party to a 1-for-10 reverse stock split that became effective on June 20, 2025 https://stocktwits.com/G101SPM/message/584123172 CHANGE EXIT TO $12.00 (midterm)

$UNCY [Again] Four months of relatively quiet consolidation, now with a (the) known catalyst timed for 1H-2026. Investors do not need an outsized (i.e. nerve-racking) position here, but it is definitely a Company worth considering (IMO). There will likely come a day in the not-too-distant future, when investors will wake to a 100-300% day on FDA approval, and perhaps a continuation thereafter. In the interim-DCA into your target position and have 6-12mo patience.

$UNCY Still holding quite a few shares. Had a good profit at $6 but still holding

$UNCY probably the 11th hour before they resubmit ?

$UNCY holding nicely, 🤑🤑🤑

$COCH Much like $UNCY there are very few posts on this board, and I really do not mind. Read about the Company and you will see the stock is now trading at/around ATL, Oversold on the 1YR Daily and 3YR Weekly, 50% below latest institutional equity placements. They extinguished $32M in debt, added Cash/ST through equity placements as-noted, received FDA approval on final phase of Acclaim study and continue to expand their global IP footprint on the technology. This reminds me of VTYX with the relentless downtrend on relatively low volume. Analyst PT range from 10-15X from the present valuation, and I agree - multiplier upside here on acquisition and/or successful Acclaim study completion. https://www.stocktitan.net/news/COCH/envoy-medical-reports-third-quarter-2025-financial-and-operational-mamwe52dj6a0.html

$UNCY UNCY has a very low float - wouldn't doubt if it hits analysts price targets $21-$105

$UNCY Vivo also decreased like 90% !!! I think they are escaping another dilution.

$UNCY Anyone know why Ra Capital Management, L.p. decreased shsres by -85.25 percent ????? That's a very bad news !!!

$UNCY i see some negative posts regarding less than $6 stock. Id put my energy toward much higher priced stock if i were you.

$UNCY pt is actually $52 but definitely will look mad at 25